Brivanib: all 21 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGFTerminatedNCT01367275Phase 2Results posted
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01267253Phase 2Results posted
- Brivanib Metastatic Renal Cell CarcinomaTerminatedNCT01253668Phase 2Results posted
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00888173Phase 2Results posted
- A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCompletedNCT00355238Phase 2Results posted
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Phase 2
- Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedNCT01540461Phase 1
- Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedNCT01108705Phase 3
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCompletedNCT00908752Phase 3
- First Line Hepato Cellular Carcinoma (HCC)CompletedNCT00858871Phase 3
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib TreatmentCompletedNCT00825955Phase 3
- Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerCompletedNCT00640471Phase 3
- Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedNCT00633789Phase 2
- Phase I/II Combination With Irinotecan- ErbituxCompletedNCT00594984Phase 1/2
- A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)CompletedNCT00437437Phase 1
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCompletedNCT00437424Phase 1
- A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)CompletedNCT00435669Phase 1
- Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) MalignanciesTerminatedNCT00300027Phase 1
- MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00207103Phase 1
- BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCompletedNCT00207051Phase 1